Skip to main content
Top
Published in:

01-11-2024 | Breast Cancer | Review Article

Personalized treatment approach for HER2-positive metastatic breast cancer

Authors: Prashant Pandey, Rishabh Chaudhary, Devika Tripathi, Kousalya Lavudi, Kamal Dua, Michael Weinfeld, Afsaneh Lavasanifar, P. S. Rajinikanth

Published in: Medical Oncology | Issue 11/2024

Login to get access

Abstract

Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.

Graphical abstract

Literature
1.
go back to reference Yu Y, et al. Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2022;14:417–32.PubMed Yu Y, et al. Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2022;14:417–32.PubMed
3.
go back to reference Deepak P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59: 101837.CrossRef Deepak P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59: 101837.CrossRef
4.
go back to reference Gradishar WJ, et al. "NCCN Guidelines® insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484–93.PubMedCrossRef Gradishar WJ, et al. "NCCN Guidelines® insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484–93.PubMedCrossRef
5.
go back to reference Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PJDDT. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today. 2022;27:2526.PubMedCrossRef Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PJDDT. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today. 2022;27:2526.PubMedCrossRef
6.
go back to reference P. Deepak et al., "c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity," p. 123160, 2023. P. Deepak et al., "c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity," p. 123160, 2023.
7.
go back to reference Murthy RK, et al. Tucatinib, Trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.PubMedCrossRef Murthy RK, et al. Tucatinib, Trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.PubMedCrossRef
10.
go back to reference Pandey P, et al. αvβ3 integrin and folate-targeted pH-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment. Bioengineering. 2024;11(8):800.PubMedPubMedCentralCrossRef Pandey P, et al. αvβ3 integrin and folate-targeted pH-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment. Bioengineering. 2024;11(8):800.PubMedPubMedCentralCrossRef
11.
go back to reference Ferrario C, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-Masley C. Novel therapies for the treatment of HER2-positive advanced breast cancer: A Canadian perspective. Curr Oncol. 2022;29(4):2720–34.PubMedPubMedCentralCrossRef Ferrario C, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-Masley C. Novel therapies for the treatment of HER2-positive advanced breast cancer: A Canadian perspective. Curr Oncol. 2022;29(4):2720–34.PubMedPubMedCentralCrossRef
15.
go back to reference Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.PubMedCrossRef Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.PubMedCrossRef
16.
go back to reference Gámez-Chiachio M, Sarrió D, Moreno-Bueno GJC. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers. 2022;14(18):4543.PubMedPubMedCentralCrossRef Gámez-Chiachio M, Sarrió D, Moreno-Bueno GJC. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers. 2022;14(18):4543.PubMedPubMedCentralCrossRef
17.
go back to reference Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.PubMedCrossRef Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.PubMedCrossRef
18.
go back to reference Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.PubMedCrossRef Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.PubMedCrossRef
20.
go back to reference Miles D, et al. "Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245–55.PubMedCrossRef Miles D, et al. "Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245–55.PubMedCrossRef
21.
go back to reference Tripathy D, et al. De Novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist. 2020;25(2):e214–22.PubMedCrossRef Tripathy D, et al. De Novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist. 2020;25(2):e214–22.PubMedCrossRef
22.
go back to reference Wong Y, et al. Long-term survival of De Novo stage IV Human Epidermal Growth Receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313–8.PubMedCrossRef Wong Y, et al. Long-term survival of De Novo stage IV Human Epidermal Growth Receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313–8.PubMedCrossRef
23.
go back to reference Battisti NML, Tong D, Ring A, Smith I. "Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401–8.PubMedCrossRef Battisti NML, Tong D, Ring A, Smith I. "Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401–8.PubMedCrossRef
24.
go back to reference Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE. "Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24(6):751–7.PubMedCrossRef Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE. "Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24(6):751–7.PubMedCrossRef
25.
27.
go back to reference Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.PubMedCrossRef Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.PubMedCrossRef
28.
go back to reference Cardama GA, et al. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. Crit Rev Oncol/Hematol. 2018;124:29–36.PubMedCrossRef Cardama GA, et al. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. Crit Rev Oncol/Hematol. 2018;124:29–36.PubMedCrossRef
30.
go back to reference Deepak P, et al. Pentapeptide cRGDfK-surface engineered nanostructured lipid carriers as an efficient tool for targeted delivery of tyrosine kinase inhibitor for battling hepatocellular carcinoma. Int J Nanomed. 2023;18:7021–46.CrossRef Deepak P, et al. Pentapeptide cRGDfK-surface engineered nanostructured lipid carriers as an efficient tool for targeted delivery of tyrosine kinase inhibitor for battling hepatocellular carcinoma. Int J Nanomed. 2023;18:7021–46.CrossRef
31.
go back to reference Baselga J, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.PubMedCrossRef Baselga J, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.PubMedCrossRef
32.
go back to reference Loibl S, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27(8):1519–25.PubMedPubMedCentralCrossRef Loibl S, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27(8):1519–25.PubMedPubMedCentralCrossRef
33.
go back to reference Niikura N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593–9.PubMedCrossRef Niikura N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593–9.PubMedCrossRef
34.
go back to reference Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71.PubMedCrossRef Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71.PubMedCrossRef
35.
go back to reference Cortés J, et al. Efficacy and safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6(8):1203–9.PubMedCrossRef Cortés J, et al. Efficacy and safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6(8):1203–9.PubMedCrossRef
36.
go back to reference Saura C, et al. Neratinib Plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.PubMedPubMedCentralCrossRef Saura C, et al. Neratinib Plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.PubMedPubMedCentralCrossRef
37.
go back to reference Narayan P, et al. US food and drug administration approval summary: Fam-Trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41(11):2108–16.PubMedCrossRef Narayan P, et al. US food and drug administration approval summary: Fam-Trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41(11):2108–16.PubMedCrossRef
38.
go back to reference Tripathi D, et al. A promising approach of dermal targeting of antipsoriatic drugs via engineered nanocarriers drug delivery systems for tackling psoriasis. Drug Metab Bioanal Lett. 2023;16(2):89–104.PubMedCrossRef Tripathi D, et al. A promising approach of dermal targeting of antipsoriatic drugs via engineered nanocarriers drug delivery systems for tackling psoriasis. Drug Metab Bioanal Lett. 2023;16(2):89–104.PubMedCrossRef
39.
go back to reference Goldberg RM, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018;3(4): e000353.PubMedPubMedCentralCrossRef Goldberg RM, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018;3(4): e000353.PubMedPubMedCentralCrossRef
40.
go back to reference Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.PubMedCrossRef Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.PubMedCrossRef
41.
go back to reference Junttila TT, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–40.PubMedCrossRef Junttila TT, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–40.PubMedCrossRef
42.
go back to reference Diéras V, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42.PubMedPubMedCentralCrossRef Diéras V, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42.PubMedPubMedCentralCrossRef
43.
go back to reference André F, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.PubMedCrossRef André F, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.PubMedCrossRef
45.
go back to reference Krop IE, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Cancers. 2014;15(7):689–99. Krop IE, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Cancers. 2014;15(7):689–99.
46.
go back to reference Nadal-Serrano M, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers (Basel). 2020;12(3):670.PubMedCrossRef Nadal-Serrano M, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers (Basel). 2020;12(3):670.PubMedCrossRef
47.
go back to reference Xu Z, et al. Novel HER2-targeting antibody-drug conjugates of Trastuzumab beyond T-DM1 in breast cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183: 111682.PubMedCrossRef Xu Z, et al. Novel HER2-targeting antibody-drug conjugates of Trastuzumab beyond T-DM1 in breast cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183: 111682.PubMedCrossRef
48.
go back to reference Saura C, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol. 2018;36:1014.CrossRef Saura C, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol. 2018;36:1014.CrossRef
49.
go back to reference Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21.PubMedCrossRef Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21.PubMedCrossRef
50.
go back to reference Cortés J, et al. Trastuzumab Deruxtecan versus Trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54.PubMedCrossRef Cortés J, et al. Trastuzumab Deruxtecan versus Trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54.PubMedCrossRef
51.
52.
go back to reference Witzel I, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer. 2014;14(1):806.PubMedPubMedCentralCrossRef Witzel I, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer. 2014;14(1):806.PubMedPubMedCentralCrossRef
54.
go back to reference Lin NU, et al. Intracranial efficacy and survival with tucatinib plus Trastuzumab and Capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.PubMedPubMedCentralCrossRef Lin NU, et al. Intracranial efficacy and survival with tucatinib plus Trastuzumab and Capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.PubMedPubMedCentralCrossRef
55.
go back to reference Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23–8.PubMedCrossRef Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23–8.PubMedCrossRef
56.
go back to reference Swain SM, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21.PubMedPubMedCentralCrossRef Swain SM, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21.PubMedPubMedCentralCrossRef
57.
go back to reference Pestalozzi BC, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14(3):244–8.PubMedCrossRef Pestalozzi BC, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14(3):244–8.PubMedCrossRef
58.
go back to reference von Minckwitz G, et al. Trastuzumab Emtansine for Residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRef von Minckwitz G, et al. Trastuzumab Emtansine for Residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRef
59.
go back to reference Rugo HS, et al. Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–84.PubMedCrossRef Rugo HS, et al. Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–84.PubMedCrossRef
60.
go back to reference Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021;2(2):139–55.PubMedPubMedCentral Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021;2(2):139–55.PubMedPubMedCentral
61.
go back to reference Kyriazoglou A, et al. Immunotherapy in HER2-positive breast cancer: a systematic review. Breast Care. 2022;17(1):63–70.PubMedCrossRef Kyriazoglou A, et al. Immunotherapy in HER2-positive breast cancer: a systematic review. Breast Care. 2022;17(1):63–70.PubMedCrossRef
62.
go back to reference Agostinetto E, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel). 2022;14(9):2136.PubMedCrossRef Agostinetto E, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel). 2022;14(9):2136.PubMedCrossRef
63.
go back to reference You Z, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):489.PubMedPubMedCentralCrossRef You Z, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):489.PubMedPubMedCentralCrossRef
64.
go back to reference Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.PubMedCrossRef Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.PubMedCrossRef
65.
go back to reference Szöőr Á, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 2020;484:1–8.PubMedCrossRef Szöőr Á, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 2020;484:1–8.PubMedCrossRef
66.
go back to reference Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(5):1029–38.PubMedPubMedCentralCrossRef Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(5):1029–38.PubMedPubMedCentralCrossRef
67.
go back to reference Arenas EJ, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021;12(1):1237.PubMedPubMedCentralCrossRef Arenas EJ, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021;12(1):1237.PubMedPubMedCentralCrossRef
68.
go back to reference Hegde M, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Inves. 2016;126(8):3036–52.CrossRef Hegde M, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Inves. 2016;126(8):3036–52.CrossRef
69.
go back to reference Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93.PubMedPubMedCentralCrossRef Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93.PubMedPubMedCentralCrossRef
70.
go back to reference Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open. 2022;7(1): 100361.PubMedPubMedCentralCrossRef Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open. 2022;7(1): 100361.PubMedPubMedCentralCrossRef
71.
go back to reference Emens LA, et al. Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005–16.PubMedPubMedCentralCrossRef Emens LA, et al. Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005–16.PubMedPubMedCentralCrossRef
72.
go back to reference Salgado R, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448–54.PubMedPubMedCentralCrossRef Salgado R, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448–54.PubMedPubMedCentralCrossRef
73.
74.
75.
go back to reference Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.PubMedCrossRef Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.PubMedCrossRef
76.
go back to reference Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.PubMedCrossRef Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.PubMedCrossRef
77.
go back to reference Boyerinas B, et al. Antibody-dependent cellular cytotoxicity activity of a novel Anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–57.PubMedPubMedCentralCrossRef Boyerinas B, et al. Antibody-dependent cellular cytotoxicity activity of a novel Anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–57.PubMedPubMedCentralCrossRef
78.
go back to reference Loi S, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–82.PubMedCrossRef Loi S, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–82.PubMedCrossRef
79.
go back to reference Emens LA, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–95.PubMedCrossRef Emens LA, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–95.PubMedCrossRef
80.
go back to reference Criscitiello C, et al. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? Eur J Surg Oncol. 2015;41(10):1288–92.PubMedCrossRef Criscitiello C, et al. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? Eur J Surg Oncol. 2015;41(10):1288–92.PubMedCrossRef
84.
85.
go back to reference Lo SS, et al. "Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54.PubMedCrossRef Lo SS, et al. "Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54.PubMedCrossRef
86.
go back to reference Timmerman RD, Herman J, Cho LC. "Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedPubMedCentralCrossRef Timmerman RD, Herman J, Cho LC. "Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedPubMedCentralCrossRef
88.
go back to reference S. J. Chmura et al., NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). vol. 40, pp. 1007-1007, 2022. S. J. Chmura et al., NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). vol. 40, pp. 1007-1007, 2022.
90.
go back to reference Kobayashi T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37.PubMedCrossRef Kobayashi T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37.PubMedCrossRef
91.
go back to reference Hanrahan EO, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas MD Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104(6):1158–71.PubMedCrossRef Hanrahan EO, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas MD Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104(6):1158–71.PubMedCrossRef
92.
go back to reference Krug D, et al. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–6.PubMedPubMedCentral Krug D, et al. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–6.PubMedPubMedCentral
93.
go back to reference Freedman GM, Jones JA, Taunk NK. Stereotactic radiation for oligometastatic and oligoprogressive stage IV breast cancer: a case-based review. Curr Oncol. 2023;30(2):2510–23.PubMedPubMedCentralCrossRef Freedman GM, Jones JA, Taunk NK. Stereotactic radiation for oligometastatic and oligoprogressive stage IV breast cancer: a case-based review. Curr Oncol. 2023;30(2):2510–23.PubMedPubMedCentralCrossRef
94.
go back to reference Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.PubMedCrossRef Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.PubMedCrossRef
95.
go back to reference Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.PubMedCrossRef Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.PubMedCrossRef
96.
go back to reference Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med. 2020;145(6):678–86.CrossRef Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med. 2020;145(6):678–86.CrossRef
97.
go back to reference Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet. 2019;95(6):643–60.PubMedCrossRef Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet. 2019;95(6):643–60.PubMedCrossRef
98.
99.
go back to reference De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–86.PubMedCrossRef De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–86.PubMedCrossRef
100.
102.
go back to reference Armakolas A, Kotsari M, Koskinas J. Liquid biopsies, novel approaches and future directions. Cancers (Basel). 2023;15(5):1579.PubMedCrossRef Armakolas A, Kotsari M, Koskinas J. Liquid biopsies, novel approaches and future directions. Cancers (Basel). 2023;15(5):1579.PubMedCrossRef
103.
go back to reference Jacot W, et al. Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer. Clin Chem. 2020;66(8):1093–101.PubMedCrossRef Jacot W, et al. Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer. Clin Chem. 2020;66(8):1093–101.PubMedCrossRef
104.
go back to reference Rodriguez BJ, et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019;8(8):1183.PubMedCrossRef Rodriguez BJ, et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019;8(8):1183.PubMedCrossRef
106.
go back to reference Chin YM, et al. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021;112(1):454–64.PubMedCrossRef Chin YM, et al. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021;112(1):454–64.PubMedCrossRef
107.
go back to reference Rothé F, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO Phase III trial. Clin Cancer Res. 2019;25(12):3581–8.PubMedCrossRef Rothé F, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO Phase III trial. Clin Cancer Res. 2019;25(12):3581–8.PubMedCrossRef
108.
go back to reference Chen Z, et al. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Mol Genet Genomic Med. 2020;8(2): e1079.PubMedCrossRef Chen Z, et al. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Mol Genet Genomic Med. 2020;8(2): e1079.PubMedCrossRef
109.
go back to reference Turner NC, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–308.PubMedPubMedCentralCrossRef Turner NC, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–308.PubMedPubMedCentralCrossRef
110.
go back to reference André F, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208–17.PubMedCrossRef André F, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208–17.PubMedCrossRef
112.
go back to reference Madhavan D, et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis. 2016;37(5):461–70.PubMedCrossRef Madhavan D, et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis. 2016;37(5):461–70.PubMedCrossRef
113.
go back to reference Ozawa PMM, et al. Identification of miRNAs enriched in extracellular vesicles derived from serum samples of breast cancer patients. Biomolecules. 2020;10(1):150.PubMedPubMedCentralCrossRef Ozawa PMM, et al. Identification of miRNAs enriched in extracellular vesicles derived from serum samples of breast cancer patients. Biomolecules. 2020;10(1):150.PubMedPubMedCentralCrossRef
114.
go back to reference Zou X, et al. Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene. 2020;722: 144104.PubMedCrossRef Zou X, et al. Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene. 2020;722: 144104.PubMedCrossRef
115.
go back to reference Hirschfeld M, et al. Urinary exosomal MicroRNAs as potential non-invasive biomarkers in breast cancer detection. Mol Diagn Ther. 2020;24(2):215–32.PubMedCrossRef Hirschfeld M, et al. Urinary exosomal MicroRNAs as potential non-invasive biomarkers in breast cancer detection. Mol Diagn Ther. 2020;24(2):215–32.PubMedCrossRef
116.
go back to reference Chanteloup G, et al. Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020;9(1):1766192.PubMedPubMedCentralCrossRef Chanteloup G, et al. Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020;9(1):1766192.PubMedPubMedCentralCrossRef
117.
go back to reference Zou X, et al. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis. Cancer Biomark. 2021;30(1):41–53.PubMedCrossRef Zou X, et al. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis. Cancer Biomark. 2021;30(1):41–53.PubMedCrossRef
118.
go back to reference Ortega FG, et al. Sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 dual determination on extracellular vesicles from breast cancer patients. Anal Chem. 2021;93(2):1143–53.PubMedCrossRef Ortega FG, et al. Sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 dual determination on extracellular vesicles from breast cancer patients. Anal Chem. 2021;93(2):1143–53.PubMedCrossRef
119.
go back to reference Tian F, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;12(1):2536.PubMedPubMedCentralCrossRef Tian F, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;12(1):2536.PubMedPubMedCentralCrossRef
120.
go back to reference Todorova VK, et al. Circulating exosomal micrornas as predictive biomarkers of neoadjuvant chemotherapy response in breast cancer. Curr Oncol. 2022;29(2):613–30.PubMedPubMedCentralCrossRef Todorova VK, et al. Circulating exosomal micrornas as predictive biomarkers of neoadjuvant chemotherapy response in breast cancer. Curr Oncol. 2022;29(2):613–30.PubMedPubMedCentralCrossRef
121.
go back to reference Müller V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6): 100299.PubMedPubMedCentralCrossRef Müller V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6): 100299.PubMedPubMedCentralCrossRef
122.
go back to reference T. Fehm et al., Abstract PD3–12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. Cancer Research, vol. 81, no. 4_Supplement, pp. PD3–12-PD3–12, 2021. T. Fehm et al., Abstract PD3–12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. Cancer Research, vol. 81, no. 4_Supplement, pp. PD3–12-PD3–12, 2021.
123.
go back to reference Wang C, et al. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020;181(3):679–89.PubMedPubMedCentralCrossRef Wang C, et al. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020;181(3):679–89.PubMedPubMedCentralCrossRef
124.
go back to reference Jacot W, et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 2019;21(1):121.PubMedPubMedCentralCrossRef Jacot W, et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 2019;21(1):121.PubMedPubMedCentralCrossRef
125.
go back to reference Pestrin M, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283–9.PubMedCrossRef Pestrin M, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283–9.PubMedCrossRef
126.
go back to reference Munzone E, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer. 2012;12(5):340–6.PubMedCrossRef Munzone E, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer. 2012;12(5):340–6.PubMedCrossRef
127.
go back to reference Allegretti M, et al. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer. 2021;20(1):151.PubMedPubMedCentralCrossRef Allegretti M, et al. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer. 2021;20(1):151.PubMedPubMedCentralCrossRef
130.
go back to reference Liu J, et al. Circulating Tumor Cells (CTCs): A unique model of cancer metastases and non-invasive biomarkers of therapeutic response. Front Genet. 2021;12: 734595.PubMedPubMedCentralCrossRef Liu J, et al. Circulating Tumor Cells (CTCs): A unique model of cancer metastases and non-invasive biomarkers of therapeutic response. Front Genet. 2021;12: 734595.PubMedPubMedCentralCrossRef
132.
go back to reference Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10):2877.PubMedPubMedCentralCrossRef Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10):2877.PubMedPubMedCentralCrossRef
133.
go back to reference Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.PubMedCrossRef Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.PubMedCrossRef
134.
go back to reference Abbosh C, et al. Correction: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2018;554(7691):264–264.PubMedCrossRef Abbosh C, et al. Correction: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2018;554(7691):264–264.PubMedCrossRef
135.
go back to reference Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev. 2013;39(7):691–700.PubMedCrossRef Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev. 2013;39(7):691–700.PubMedCrossRef
136.
go back to reference Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.PubMedCrossRef Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.PubMedCrossRef
137.
go back to reference Giuliano M, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014;16(5):440.PubMedPubMedCentralCrossRef Giuliano M, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014;16(5):440.PubMedPubMedCentralCrossRef
138.
go back to reference Larsson AM, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20(1):48.PubMedPubMedCentralCrossRef Larsson AM, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20(1):48.PubMedPubMedCentralCrossRef
139.
go back to reference Mu Z, et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015;154(3):563–71.PubMedCrossRef Mu Z, et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015;154(3):563–71.PubMedCrossRef
140.
go back to reference Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433.PubMedPubMedCentralCrossRef Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433.PubMedPubMedCentralCrossRef
141.
go back to reference Galardi F, et al. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021;23(1):38.PubMedPubMedCentralCrossRef Galardi F, et al. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021;23(1):38.PubMedPubMedCentralCrossRef
142.
go back to reference Dirix L, et al. Circulating tumor cell detection: A prospective comparison between Cell Search® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022;193(2):437–44.PubMedPubMedCentralCrossRef Dirix L, et al. Circulating tumor cell detection: A prospective comparison between Cell Search® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022;193(2):437–44.PubMedPubMedCentralCrossRef
144.
go back to reference Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.PubMedCrossRef Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.PubMedCrossRef
Metadata
Title
Personalized treatment approach for HER2-positive metastatic breast cancer
Authors
Prashant Pandey
Rishabh Chaudhary
Devika Tripathi
Kousalya Lavudi
Kamal Dua
Michael Weinfeld
Afsaneh Lavasanifar
P. S. Rajinikanth
Publication date
01-11-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 11/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02504-4

Other articles of this Issue 11/2024

Medical Oncology 11/2024 Go to the issue

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more